Celyad SA (Belgium) Performance
CYAD Stock | EUR 0.77 0.01 1.28% |
Celyad SA holds a performance score of 13 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 6.09, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Celyad SA will likely underperform. Use Celyad SA jensen alpha, sortino ratio, and the relationship between the standard deviation and total risk alpha , to analyze future returns on Celyad SA.
Risk-Adjusted Performance
13 of 100
Weak | Strong |
Very Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Celyad SA are ranked lower than 13 (%) of all global equities and portfolios over the last 90 days. Even with relatively weak basic indicators, Celyad SA reported solid returns over the last few months and may actually be approaching a breakup point. ...more
Begin Period Cash Flow | 17.2 M | |
Total Cashflows From Investing Activities | -126 K |
Celyad |
Celyad SA Relative Risk vs. Return Landscape
If you would invest 25.00 in Celyad SA on September 19, 2024 and sell it today you would earn a total of 52.00 from holding Celyad SA or generate 208.0% return on investment over 90 days. Celyad SA is generating 2.641% of daily returns and assumes 15.083% volatility on return distribution over the 90 days horizon. Simply put, majority of traded equity instruments are less risky than Celyad on the basis of their historical return distribution, and most equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
Risk |
Celyad SA Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Celyad SA's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Celyad SA, and traders can use it to determine the average amount a Celyad SA's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1751
Best Portfolio | Best Equity | |||
Good Returns | CYAD | |||
Average Returns | ||||
Small Returns | ||||
Cash | Small Risk | Average Risk | High Risk | Huge Risk |
Negative Returns |
Estimated Market Risk
15.08 actual daily | 96 96% of assets are less volatile |
Expected Return
2.64 actual daily | 52 52% of assets have lower returns |
Risk-Adjusted Return
0.18 actual daily | 13 87% of assets perform better |
Based on monthly moving average Celyad SA is performing at about 13% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Celyad SA by adding it to a well-diversified portfolio.
Celyad SA Fundamentals Growth
Celyad Stock prices reflect investors' perceptions of the future prospects and financial health of Celyad SA, and Celyad SA fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Celyad Stock performance.
Return On Equity | -0.93 | |||
Return On Asset | -0.29 | |||
Current Valuation | 11.19 M | |||
Shares Outstanding | 22.59 M | |||
Price To Earning | (22.41) X | |||
Price To Book | 0.76 X | |||
Price To Sales | 22,298 X | |||
EBITDA | (24.73 M) | |||
Cash And Equivalents | 12.13 M | |||
Cash Per Share | 0.85 X | |||
Total Debt | 3.4 M | |||
Debt To Equity | 0.13 % | |||
Book Value Per Share | 1.36 X | |||
Cash Flow From Operations | (26.64 M) | |||
Earnings Per Share | (1.44) X | |||
Total Asset | 79.94 M | |||
Current Asset | 109.42 M | |||
Current Liabilities | 11.49 M | |||
About Celyad SA Performance
Assessing Celyad SA's fundamental ratios provides investors with valuable insights into Celyad SA's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Celyad SA is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor-T cell-based therapies for the treatment of cancer. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium. CELYAD ONCOLOGY operates under Biotechnology classification in Belgium and is traded on Brussels Stock Exchange. It employs 87 people.Things to note about Celyad SA performance evaluation
Checking the ongoing alerts about Celyad SA for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Celyad SA help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.Celyad SA is way too risky over 90 days horizon | |
Celyad SA has some characteristics of a very speculative penny stock | |
Celyad SA appears to be risky and price may revert if volatility continues | |
Net Loss for the year was (26.51 M) with profit before overhead, payroll, taxes, and interest of 5 K. | |
Celyad SA has accumulated about 12.13 M in cash with (26.64 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.85, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing Celyad SA's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Celyad SA's stock is overvalued or undervalued compared to its peers.
- Examining Celyad SA's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Celyad SA's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Celyad SA's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Celyad SA's stock. These opinions can provide insight into Celyad SA's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Celyad Stock Analysis
When running Celyad SA's price analysis, check to measure Celyad SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Celyad SA is operating at the current time. Most of Celyad SA's value examination focuses on studying past and present price action to predict the probability of Celyad SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Celyad SA's price. Additionally, you may evaluate how the addition of Celyad SA to your portfolios can decrease your overall portfolio volatility.